+

WO2006046978A3 - Cationic peptide-mediated transformation - Google Patents

Cationic peptide-mediated transformation Download PDF

Info

Publication number
WO2006046978A3
WO2006046978A3 PCT/US2005/022705 US2005022705W WO2006046978A3 WO 2006046978 A3 WO2006046978 A3 WO 2006046978A3 US 2005022705 W US2005022705 W US 2005022705W WO 2006046978 A3 WO2006046978 A3 WO 2006046978A3
Authority
WO
WIPO (PCT)
Prior art keywords
cationic peptide
cells
mediated transformation
cationic
cationic peptides
Prior art date
Application number
PCT/US2005/022705
Other languages
French (fr)
Other versions
WO2006046978A2 (en
Inventor
Charles Nicolette
Irina Tcherepanova
Original Assignee
Argos Therapeutics Inc
Charles Nicolette
Irina Tcherepanova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics Inc, Charles Nicolette, Irina Tcherepanova filed Critical Argos Therapeutics Inc
Publication of WO2006046978A2 publication Critical patent/WO2006046978A2/en
Publication of WO2006046978A3 publication Critical patent/WO2006046978A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides novel methods of cationic peptide-mediated transformation of RNA into cells, cationic peptides useful in such methods, related noncovalent cationic peptide-nucleic acid complexes and cells transformed with such complexes. The invention further provides novel cationic peptides containing embedded MHC helper epitopes. Such cationic peptides are particularly useful for the transformation of antigen presenting cells, such as dendritic cells.
PCT/US2005/022705 2004-06-28 2005-06-28 Cationic peptide-mediated transformation WO2006046978A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58357904P 2004-06-28 2004-06-28
US60/583,579 2004-06-28

Publications (2)

Publication Number Publication Date
WO2006046978A2 WO2006046978A2 (en) 2006-05-04
WO2006046978A3 true WO2006046978A3 (en) 2008-11-06

Family

ID=36228191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/022705 WO2006046978A2 (en) 2004-06-28 2005-06-28 Cationic peptide-mediated transformation

Country Status (1)

Country Link
WO (1) WO2006046978A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
AR069704A1 (en) 2007-12-18 2010-02-10 Alcon Res Ltd SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
JP2012509904A (en) * 2008-11-26 2012-04-26 ユニバーシティ・オブ・カンザス Nucleic acid delivery composition and nucleic acid delivery method
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
MX336839B (en) 2010-07-30 2016-02-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation.
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3590949T3 (en) 2010-10-01 2022-07-11 Modernatx Inc RIBONUCLEIC ACIDS CONTAINING N1-METHYL-PSEUDOURACIL AND USE THEREOF
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
JP2014511687A (en) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acid delivery and formulation
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (en) 2011-10-03 2022-04-29 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN110201187A (en) 2011-12-16 2019-09-06 现代泰克斯公司 Modified nucleosides, nucleotide and nucleic acid compositions
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
LT2922554T (en) 2012-11-26 2022-06-27 Modernatx, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG10201801431TA (en) 2013-08-21 2018-04-27 Curevac Ag Respiratory syncytial virus (rsv) vaccine
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
CA2927292C (en) 2013-11-08 2020-09-15 Bank Of Canada Optically variable devices, their production and use
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083232A1 (en) * 1999-09-09 2001-03-14 Jung, Günther, Prof. Dr. Transfer of mRNA using polycationic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083232A1 (en) * 1999-09-09 2001-03-14 Jung, Günther, Prof. Dr. Transfer of mRNA using polycationic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HASHIDA H. ET AL.: "Fusion of HIV-1 tat protein transduction domain to poly-lysine as a new DNA delivery tool", BR. J. CANCER, vol. 90, no. 6, 2004, pages 1252 - 1258, XP002297597 *
UNNAMALA I. ET AL.: "Cationic oligopeptide-mediated delivery of dsRNA for post-transcriptional gene silencing in plant cells", FEBS LETT., vol. 566, 2004, pages 307 - 310, XP004509368 *

Also Published As

Publication number Publication date
WO2006046978A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
WO2006046978A3 (en) Cationic peptide-mediated transformation
WO2006102163A3 (en) Transfection reagents for non-adherent suspension cells
WO2006082406A3 (en) Human antibodies and proteins
WO2008042973A3 (en) Lipid containing formulations
WO2009022154A3 (en) Peptide with multiple epitopes
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
WO2001085203A3 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
WO2007024941A3 (en) Polyvalent vaccine
WO2007028574A3 (en) Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
WO2006138004A3 (en) Immunogenic compositions for chlamydia trachomatis
WO2007076032A3 (en) Compositions and methods for producing a composition
WO2004081028A3 (en) Allergen peptide fragments and use thereof
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
WO2006047515A3 (en) Dendritic cells loaded with heat shocked melanoma cell bodies
SG126893A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
EP1572918A4 (en) Synthetic glyco-lipo-peptides as vaccines
WO2008080091A3 (en) Activation of rig-i pathway
WO2006076628A3 (en) Compositions comprising promoter sequences and methods of use
EP2481748A3 (en) Foxp3 peptide vaccine
WO2005017130A3 (en) Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
WO2010032008A3 (en) Dendritic cell modulatory molecule
WO2006054096A3 (en) Soluble bifunctional proteins
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
WO2006120473A3 (en) Mhc class i and ii peptide antigens derived from tumour antigen 5t4
WO2005000870A3 (en) Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KM KR KZ LC LK LR LS LT LU LV MA MG MK MN MW MX MZ NA NG NI NZ OM PG PH PL PT RO RU SC SD SE SK SL SM SY TJ TM TN TR TT TZ UA US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载